{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 29 of 51', 'Study ID RCB: 2020-A00652-37', 'The Dermatology Quality of Life Index (DLQI) is well recognized Quality of Life questionnaire', 'in psoriasis and capture a combination of symptoms, impact on daily routines, and feeling of', 'stigmatization. It is a simple 10-question validated questionnaire that has been used in over', '40 different skin conditions in over 80 countries and is available in over 90 languages. Its use', 'has been described in over 1000 publications including many multinational studies. It is', 'recommended to provide indirect measure of disease severity and is well used in studies on', 'psoriasis and mentioned in the UK-treatment guideline (for details, see section 9.1.3).', 'The PSO-TARGET QoL component grid is a novel tool designed using a retrospective survey', \"based on the recollection and experience from 3 clinical dermatologists of patient's\", 'expectations. It contains 12 therapeutic goals equally distributed into the 4 major', 'psychometric components classically used in quality of life studies in patients suffering from', 'chronic diseases (Chassany, 2003; Forestier et al., 2019). These four dimensions are: physical,', 'subjective, relational/social and therapeutic. It has never been used before since it was', 'designed for the PSO-TARGET study. Each patient will be required to pick only one item in the', 'grid as his/her main therapeutic goal (see section 9.1.2). Treatment satisfaction in regards to', 'the chosen component will be assessed at 12/16 weeks and 52 weeks by a 4 points Likert Scale', 'and the level of concordance will be compared to DLQI scoring classes (described in section', '9.1.2).', '9.5 Study Size', 'The main criterion is the sensitivity of the PSO-TARGET tool (percentage of patients who', 'consider their target objective as being achieved after 12/16 weeks of treatment as defined', 'by a \"satisfied or very satisfied\" response, assessed on a 4 points Likert scale, among patients', 'with a DLQI total score of 0 or 1).', 'The sample size calculation is based on the following hypotheses:', 'Sensitivity: 90%', 'Absolute precision : 10%', 'Type I error : 5%', 'Power at 80%', 'Prevalence: 80% (estimated rate of patient with a DLQI 0-1 after 12 weeks of treatment)', 'Hypothesis :', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 30 of 51', 'Study ID RCB: 2020-A00652-37', 'HO : Se = SeO', 'H1 : Se = Se1 > SeO', 'With Se=sensitivity, Se0=0.8 and Se1=0.9', 'Using the binomial probability formula, the sample size necessary to meet both a significance', 'level and a power requirement may be found by solving the following two equations', 'simultaneously :', 'Significance level B ( s1 > S a I n1, Se0) = a', 'B (s1 > S a I n1, Se1) = 1 - \u00df', 'Where n1 : patients with a DLQI 0-1, s1 : patients with a DLQI 0-1 and a positive test outcome', 'With =0.05 and 1 - \u00df=0.8', 'To obtain n, n1 is inflated by the prevalence P (rate of patients with a DLQI 0-1 = 80%), to', 'obtain n = n1 / P', 'The software used is PASS version 12, using the Li and Fine method (Li and Fine, 2004).', 'Based on these hypotheses, the sample size needed is estimated at 134 evaluable patients.', 'Assuming 10% of patients will not be evaluable on main criterion, 150 patients have to be', 'included.', '9.6 Data Management', 'The Study Site will receive data collection tools (CRFs, questionnaires) from CLINACT.', 'Whenever possible, complete data sets should be entered. Text field entries and any data', 'collected on paper should be legible and follow the requested language standard.', 'The Study Site Responsible must sign off the complete data set reported by the site for each', 'patient, confirming the collected data. Adverse Event and Other experiences reported', 'according to section 11 should be signed off separately by a physician involved in the study. A', 'causality evaluation should always be provided.', 'Data Management will be carried out according to a Data Management Plan which will be', 'written and approved before the design of the study database is finalized. The data', 'management provider should approve all data formats before the data collection tools are', 'made available to the sites.', 'If the written informed consent of a patient is known not to be available in spite of it being', 'required, data for this patient is not entered into or is deleted from the database.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}